New: Seletracetam Review Published in CNS Drugs Read More →
Home About Pipeline Team News Contact Us
Epilepsy Therapeutics

First-in-class treatments for unmet needs in epilepsy

Founded by world-renowned epilepsy experts — including discoverers of Keppra and ezogabine — PrevEp develops paradigm-changing therapies for seizure prevention and treatment.

Explore Our Pipeline Learn More
Scroll
Our Mission

Developing paradigm-changing therapies

PrevEp combines deep expertise in basic science, drug development, and clinical trials to address critical unmet needs in epilepsy.

Intranasal seletracetam spray

Preemptive Seizure Treatment

Intranasal seletracetam spray — a rapid-onset, non-sedating, non-addictive preemptive treatment for predictable seizures.

Lead Program Orphan potential
Brain neural network visualization

Epilepsy Prevention

Network pharmacology approach using safe, FDA-cleared combination therapies targeting multiple epileptogenic mechanisms.

Multi-target TBI & Stroke
Newborn in NICU with IV treatment

Neonatal Seizure Treatment

Novel intravenous topiramate formulation for neonatal seizures — addressing increased mortality and lifelong brain damage risk.

IV Formulation Orphan Drug
About PrevEp

Founded by pioneers in epilepsy science

Our founders include the discoverers of levetiracetam (Keppra) — the world's most prescribed anti-seizure medication — and ezogabine/retigabine, the first KCNQ/Kv7 channel opener.

Together, the PrevEp team brings over 150+ combined years of translational epilepsy research, drug development, and clinical trial leadership.

Meet Our Team →
0
Combined Years of Experience
0
Programs in Pipeline
0
Co-founders
#1
Ranked Scholar in Epilepsy
Focus Areas

Three therapeutic priorities

Addressing the most critical unmet needs across the epilepsy care spectrum.

500K patients/year US

Post-traumatic & Post-stroke Epilepsy

Next need: prevention of epilepsy following traumatic brain injury and stroke.

1.7M patients

Acute Prevention of Seizures

Paradigm shift in epilepsy to preemptive treatment of predictable seizures.

10K babies/year US

Neonatal Seizures

Unmet need: seizure control when standard of care fails.

Our Pipeline

Five programs addressing critical unmet needs

Each program targets a distinct gap in epilepsy care, from preemptive seizure treatment to disease prevention.

Novel Network Pharmacology

PrevEp002

Atorvastatin, Ceftriaxone, Levetiracetam

Epilepsy prevention — validated in two models and two species. Network pharmacology approach combining safe, FDA-cleared molecules targeting multiple epileptogenic mechanisms.

PrevEp003 Paused

Levetiracetam, Topiramate, Gabapentin

Epilepsy prevention — validated in a rodent model. Combination therapy targeting multiple epileptogenic mechanisms for post-traumatic epilepsy prevention.

Novel Intravenous Formulation

PrevEp004

IV Topiramate

Neonatal seizures and status epilepticus. Orphan Drug Designation in US and Europe. Safety and efficacy validated in oral formulation1.

PrevEp005 Seeking Outlicense Partner

IV Atorvastatin

First intravenous statin therapy. Novel IV atorvastatin formulation for hospitalized patients unable to take oral statins.

Novel Intranasal Formulation

PrevEp006

Seletracetam

Acute repetitive seizures REST. First non-benzodiazepine intranasal seizure rescue medication.

1 Safety and efficacy validated in oral formulation

Supported by NINDS SBIR Awards: 1R43NS132659 & 1R43NS119081

Executive Team

World-class expertise in epilepsy

Our team of co-founders brings together leading minds in translational research, drug development, and clinical trials.

Pavel Klein

20+ years clinical epilepsy research. PI of largest phase 3 RCT of new anti-seizure medication. NIH and DOD-funded clinical post-traumatic epilepsy prevention trial leader.

Pavel Klein

Chief Executive Officer, Co-founder

Wolfgang Löscher

40+ years translational research. Discovered antiepileptic properties of levetiracetam (Keppra). One of the most cited epilepsy researchers globally. #1 ranked scholar in epilepsy.

Wolfgang Löscher

Chief Scientific Officer, Co-founder

Chris Rundfeldt

30+ years pharmaceutical industry experience. Discovered ezogabine/retigabine, first KCNQ/KV7 channel opener.

Chris Rundfeldt

Chief Operation Officer, Co-founder

Detlev Boison

25+ years translational epilepsy research. PI of antiepileptogenic drug discovery program with novel molecular targets.

Detlev Boison

Chief Development Officer, Co-founder

Alexander Rotenberg

20+ years of translational and clinical research experience. Professor at Harvard Medical School. Expert in transcranial magnetic stimulation biomarkers.

Alexander Rotenberg

Biomarker Development, Co-founder

Matthias Koepp

30+ years epilepsy therapeutic product development. Professor at UCL. Heads Epilepsy Clinical Trials Unit. Co-directed phase 3 post-stroke epilepsy prevention trial.

Matthias Koepp

VP Product Development, Co-founder

Eugen Trinka

30+ years epilepsy research and clinical trial experience. Chairman, Department of Neurology at Paracelsus Medical University. ILAE Vice President.

Eugen Trinka

Chief Medical Officer, Co-founder

Advisory Board

6 world-leading epilepsy experts from NYU, UC Davis, Harvard, and more.

View Advisory Board →
Board of Directors

Strategic leadership and governance

Our board brings decades of pharmaceutical executive experience, from FDA drug approvals to clinical development leadership.

Pavel Klein

20+ years clinical epilepsy research. PI of largest phase 3 RCT of new anti-seizure medication. NIH and DOD-funded clinical post-traumatic epilepsy prevention trial leader.

Pavel Klein, MD

Chairman of the Board

Pierandrea Muglia

20+ years CNS drug development leadership. Founder of GRIN Therapeutics. Led Series A financing and Phase 3 advancement. Former CMO at multiple biotech companies. 100+ publications.

Pierandrea Muglia, MD

Board Member

Enrique Carrazana

Led VALTOCO® (diazepam nasal spray) FDA approval at Neurelis. Former CMO at Acorda Therapeutics, Global Head at Novartis. Harvard Medical School graduate. 140+ publications.

Enrique Carrazana, MD

Board Member

Wolfgang Löscher

40+ years translational research. Discovered antiepileptic properties of levetiracetam (Keppra). One of the most cited epilepsy researchers globally. #1 ranked scholar in epilepsy.

Wolfgang Löscher, PhD

Board Member

Advisory Board

Guided by world-leading experts

Our advisory board comprises 6 world-leading epilepsy experts from NYU, UC Davis, Harvard, and other premier institutions, providing strategic guidance on clinical development and regulatory strategy.

Learn More About Our Advisors →
News & Updates

Latest from PrevEp

March 2026

Comprehensive Seletracetam Review Published in CNS Drugs

A detailed review of seletracetam's pharmacology, clinical profile, and the development of the novel intranasal formulation published in CNS Drugs, covering preclinical and first-in-human data.

Read More
January 2026

Wolfgang Löscher Named #1 Ranked Scholar in Epilepsy

PrevEp's Chief Scientific Officer recognized by ScholarGPS as an inaugural Highly Ranked Scholar, ranked #1 in the field of epilepsy based on publication records across 30+ million scholars.

Read More
2026

First-in-Human Intranasal Seletracetam Published in Annals of Neurology

Original clinical data from the first-in-human use of intranasal seletracetam published in Annals of Neurology — one of the most prestigious journals in neurology.

Read Paper

Supported By